SCHEMBL6811215

SCHEMBL6811215

COCCC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 5/20 0.68
▸ MAOB P27338 1/20 0.63
▸ NR4A1 P22736 1/20 0.62
▸ NR4A2 P43354 1/20 0.62
▸ NR4A3 Q92570 1/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ PARP10 Q53GL7 1/20 0.59
▸ RAB9A P51151 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ GAA P10253 1/20 0.58
▸ HTT P42858 1/20 0.58
▸ NPC1 O15118 3/20 0.57
▸ SRD5A2 P31213 1/20 0.57
▸ HDAC3 O15379 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC2 Q92769 1/20 0.56
▸ NCOR2 Q9Y618 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11290489 0.87 EGFR (0.66) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL10797162 0.85 MAOB (0.67) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL4152328 0.85 EGFR (0.72) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL6283205 0.84 EGFR (0.70) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL958582 0.83 EGFR (0.69) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL1557011 0.83 FFAR1 (0.71) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL6811506 0.83 EGFR (0.69) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL27517502 0.82 EGFR (0.68) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL102983 0.81 RAB9A (0.83) EGFRMAOBNR4A1NR4A2NR4A3
SCHEMBL23782481 0.81 EGFR (0.67) EGFRMAOBNR4A1NR4A2NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0828513-B1 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER (US) 2004-01-21 — — EP disclosed
EP-0777652-B1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER (US) 2003-06-25 — — EP disclosed
US-6258827-B1 HYDROXYAROMATIC HETEROCYCLIC ALKANOLS AND LEVODOPA PFIZER INC. 2001-07-10 — — US disclosed
US-6046213-A Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives PFIZER INC. (US) 2000-04-04 — — US disclosed
EP-0828513-A2 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER INC. (US) 1998-03-18 — — EP disclosed
EP-0777652-A1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER INC. (US) 1997-06-11 — — EP disclosed
US-5629340-A DIPHENYL FURAN COMPOUNDS TSUMURA & CO. (JP) 1997-05-13 — — US disclosed
WO-1996037226-A2 COMBINATIONS FOR THE TREATMENT OF PARKINSONISM CONTAINING SELECTIVE NMDA ANTAGONISTS PFIZER INC. (US) 1996-11-28 — — WO disclosed
WO-1996006081-A1 NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES PFIZER INC. (US) 1996-02-29 — — WO disclosed
EP-0678296-A1 VASCULARIZATION INHIBITOR AND NOVEL COMPOUND TSUMURA & CO. (JP) 1995-10-25 — — EP disclosed
Send feedback